Yersinia

Cell death is essential to your health − an immunologist explains when cells decide to die with a bang or take their quiet leave

Retrieved on: 
Wednesday, October 4, 2023
Apoptosis, Tissue, Infection, Endometriosis, DNA, Maintenance, Yersinia enterocolitica, Cell death, DSM-IV codes, Neoplasm, Black, COVID-19, Fever, Finger, Survival, Cancer, The, Black Death, Research, Cell, Lupus, Yersinia pestis, Uterus, Pain, Pandemic, Protein, Patient, Swelling, Immune system, Bacteria, Immunodeficiency, Health, Death, Yersinia, Virus, Red, Skin, Vaccine, Pharmaceutical industry

While death may seem passive, an unfortunate ending that just “happens,” the death of your cells is often extremely purposeful and strategic.

Key Points: 
  • While death may seem passive, an unfortunate ending that just “happens,” the death of your cells is often extremely purposeful and strategic.
  • The intricate details of how and why cells die can have significant effects on your overall health.
  • My own research explores how immune cells switch between different types of programmed death in scenarios like cancer or injury.

Quietly exiting: silent cell death

    • Regardless of the timeline, the death of old and damaged cells and their replacement with new cells is a normal and important bodily process.
    • Silent cell death, or apoptosis, is described as silent because these cells die without causing an inflammatory reaction.
    • Apoptosis is an active process involving many proteins and switches within the cell.
    • Sometimes cells can detect that their own functions are failing and turn on executioner proteins that chop up their own DNA, and they quietly die by apoptosis.
    • Whether it’s for development or maintenance, your cells are quietly exiting to keep your body happy and healthy.

Going out with a bang: inflammatory cell death

    • This inflammatory cell death is typically triggered by bacteria, viruses or stress.
    • Rather than quietly shutting down, cells undergoing inflammatory cell death will make themselves burst, or lyse, killing themselves and exploding inflammatory messengers as they go.
    • These infections are rarely fatal because your immune cells can aggressively eliminate the pathogen’s niche by inducing inflammatory cell death.
    • The virus behind the COVID-19 pandemic also causes a lot of inflammatory cell death.
    • Researchers are still studying the role of inflammatory cell death in COVID-19 infection, and understanding this delicate balance can help improve treatments.

ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative Pathogens

Retrieved on: 
Tuesday, June 20, 2023
MIC, XDR, Hemolysis, S. aureus, Methicillin-resistant Staphylococcus aureus, Daptomycin, MRSA, Cancer, ASM, Osteomyelitis, Acinetobacter, Yersinia pestis, Gram-negative bacteria, Staphylococcus aureus, Cons, Klebsiella pneumoniae, Pseudomonas aeruginosa, NPN, Knee, ECCMID, Animal, Lower respiratory tract infection, Patient, Ventilator-associated pneumonia, Meropenem, Fungal infection, Bacteria, Campaign, Amikacin, Food, Peptide, Staphylococcus, Vaccine, Yersinia, Burkholderia, MD, Klebsiella, Pseudomonas

“The data presented at ASM Microbe is quite powerful.

Key Points: 
  • “The data presented at ASM Microbe is quite powerful.
  • Both dose regimens of CF-370 in addition to amikacin significantly reduced bacteria counts compared to all other treatment groups (p≤0.0001).
  • The results of this study reproduce the efficacy seen in previously released data presented at ECCMID 2023 further demonstrating the bactericidal power of CF-370 against XDR strains of Gram-negative pathogens.
  • The results of this study reinforce previously released data demonstrating the power of both CF-296 and exebacase when delivered locally in the rabbit osteomyelitis model.

Insights on the Reiter's Syndrome Treatment Global Market to 2027 - Rapidly Increasing Reactive Arthritis Incidences and Rising Demand for Effective Treatment are Expected to Drive Growth - ResearchAndMarkets.com

Retrieved on: 
Friday, September 30, 2022
Health, General Health, Chlamydia trachomatis, Adult, Reactive arthritis, Inflammation, Sex, Salmonella, Sex organ, Arthritis, Campylobacter, Diarrhea, Administration, Population, Health, Growth, Market share, Syndrome, Genetically modified bacteria, Patient, CDC, Dosage form, Bacteria, Arthralgia, Inflammatory arthritis, Method, Ageing, Disease, Route of administration, CAGR, Birth control, Shigella, Yersinia

The global Reiter's syndrome treatment market is anticipated to grow at a significant CAGR during the forecast period, 2023-2027.

Key Points: 
  • The global Reiter's syndrome treatment market is anticipated to grow at a significant CAGR during the forecast period, 2023-2027.
  • The market growth can be attributed to the rising instances of reactive arthritis and advancements in treatment processes and methods.
  • Besides, advances in the healthcare industry have led to better accessibility of patient care suffering from severe conditions like reactive arthritis, contributing to the growth of the global Reiter's syndrome treatment market.
  • Rapidly increasing reactive arthritis incidences and rising demand for effective treatment are expected to drive the global Reiter's syndrome treatment market over the next five years.

Ology Bioservices Wins Two Department of Defense Awards Totaling More Than $135 Million

Retrieved on: 
Monday, April 15, 2019
Health, Biotechnology, Infectious diseases, Pharmaceutical, Defense, Contracts, Medical specialties, Medicine, Infectious diseases, Black Death, Yersinia, Yersinia pestis, Pestis, Plague, Vaccine, Monoclonal antibody

The target for this program is Plague, a disease caused by infection with the bacterium Yersinia pestis (Y. pestis).

Key Points: 
  • The target for this program is Plague, a disease caused by infection with the bacterium Yersinia pestis (Y. pestis).
  • To date, no one has successfully used monoclonal antibodies against Y. pestis as a treatment for Plague in humans, said Dr. Robert V. House, Senior Vice President, Government Contracts at Ology Bioservices.
  • Technology Award: PRISM also awarded Ology Bioservices a $5.1 million, 30-month contract entitled, Developing, Establishing and Exercising Plasmid DNA Manufacturing Capabilities at the DOD Advanced Development and Manufacturing Facility.
  • The team at Ology Bioservices has decades of experience manufacturing, developing and licensing vaccines and protein/antibody therapeutics.